Diversion and abuse of the medications used in opioid maintenance treatment (OMT) methadone (MET), mono-buprenorphine (BUP) and buprenorphine-naloxone (BNX) have been documented in countries around the world, for example in France (Auriacombe, Fatseas, Dubernet, Daulouede, & Tignol, 2004; Nordmann et al., 2012; Obadia, Perrin, Feroni, Vlahov, & Moatti, 2001; Roux et al., 2008a; Roux et al., 2008b; Vidal-Trecan, Varescon, Nabet, & Boissonnas, 2003), Australia (Aitken, Higgs, & Hellard, 2008; Degenhardt et al., 2009; Horyniak, Dietze, Larance, Winstock, & Degenhardt, 2011; Jenkinson, Clark, Fry, & Dobbin, 2005; Larance et al., 2011a; Winstock & Lea, 2010), USA (Bazazi, Yokell, Fu, Rich, & Zaller, 2011; Cicero, Surratt, & Inciardi, 2007; Dasgupta et al., 2010; Johanson, Arfken, di Menza, & Sc…
Monthly Archives: March 2015
Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients
Diversion and abuse of the medications used in opioid maintenance treatment (OMT) methadone (MET), mono-buprenorphine (BUP) and buprenorphine-naloxone (BNX) have been documented in countries around the world, for example in France (Auriacombe, Fatseas, Dubernet, Daulouede, & Tignol, 2004; Nordmann et al., 2012; Obadia, Perrin, Feroni, Vlahov, & Moatti, 2001; Roux et al., 2008a; Roux et al., 2008b; Vidal-Trecan, Varescon, Nabet, & Boissonnas, 2003), Australia (Aitken, Higgs, & Hellard, 2008; Degenhardt et al., 2009; Horyniak, Dietze, Larance, Winstock, & Degenhardt, 2011; Jenkinson, Clark, Fry, & Dobbin, 2005; Larance et al., 2011a; Winstock & Lea, 2010), USA (Bazazi, Yokell, Fu, Rich, & Zaller, 2011; Cicero, Surratt, & Inciardi, 2007; Dasgupta et al., 2010; Johanson, Arfken, di Menza, & Sc…
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.
Authors: Sullivan JG, Webster L
Abstract
PURPOSE: The purpose of this study was to provide a preliminary assessment of the safety, tolerability, symptom control, and acceptability of buprenorphine-naloxone buccal film (BBN) for the maintenance treatment of opioid dependence in patients converted from buprenorphine-naloxone sublingual tablet or film (SLBN), as well as to determine the conversion ratio for switching patients from SLBN to BBN.
METHODS: This open-label study included adult opioid-dependent subjects stabilized on 8/2 to 32/8 mg/d of SLBN for a minimum of 30 days. Study subjects were converted to a bioequivalent dose of BBN and maintained for 12 weeks.
FINDINGS: A total of 249 subjects (mean age 38.7 years, 65.9% male) were converted from SLBN to a single daily d…
Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.
Authors: Sullivan JG, Webster L
Abstract
PURPOSE: The purpose of this study was to provide a preliminary assessment of the safety, tolerability, symptom control, and acceptability of buprenorphine-naloxone buccal film (BBN) for the maintenance treatment of opioid dependence in patients converted from buprenorphine-naloxone sublingual tablet or film (SLBN), as well as to determine the conversion ratio for switching patients from SLBN to BBN.
METHODS: This open-label study included adult opioid-dependent subjects stabilized on 8/2 to 32/8 mg/d of SLBN for a minimum of 30 days. Study subjects were converted to a bioequivalent dose of BBN and maintained for 12 weeks.
FINDINGS: A total of 249 subjects (mean age 38.7 years, 65.9% male) were converted from SLBN to a single daily d…
Zubsolv (Buprenorphine and Naloxone Sublingual Tablets) – updated on RxList
(Source: RxList – New and Updated Drug Monographs)
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
Zubsolv (Buprenorphine and Naloxone Sublingual Tablets) – updated on RxList
(Source: RxList – New and Updated Drug Monographs)
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
Non-controlled and over-the-counter drugs of abuse
2.5 out of 5 stars
Abuse of Medications That Theoretically Are Without Abuse Potential. Reeves RR et al. South Med J 2015 Mar;108:151-157.
Abstract
This review of noncontrolled prescription and over-the-counter drugs that can be and have been abused for non-medical or recreational purposes is rather sketchy and anecdotal (as the authors admit,) but nevertheless contains some useful information.
Classes of drugs discussed include:
Cold & Cough products: pseudoephedrine, ephedrine, oxymetazoline, dextromethorphan
Anticholinergics: diphenhydramine, benztropine, trihexyphenidyl (Artane)
Antipsychotics: quetiapine, olanzapine
Antidepressants: tricyclics, bupropion, fluoxetine, venlafaxine
Anitconvulsants: pregabalin, gabapentin
Muscle relaxants: carisoprodol, cyclobenaprine (Flexer…
Non-controlled and over-the-counter drugs of abuse
2.5 out of 5 stars
Abuse of Medications That Theoretically Are Without Abuse Potential. Reeves RR et al. South Med J 2015 Mar;108:151-157.
Abstract
This review of noncontrolled prescription and over-the-counter drugs that can be and have been abused for non-medical or recreational purposes is rather sketchy and anecdotal (as the authors admit,) but nevertheless contains some useful information.
Classes of drugs discussed include:
Cold & Cough products: pseudoephedrine, ephedrine, oxymetazoline, dextromethorphan
Anticholinergics: diphenhydramine, benztropine, trihexyphenidyl (Artane)
Antipsychotics: quetiapine, olanzapine
Antidepressants: tricyclics, bupropion, fluoxetine, venlafaxine
Anitconvulsants: pregabalin, gabapentin
Muscle relaxants: carisoprodol, cyclobenaprine (Flexer…
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone: HIV Prevention Trials Network 058
Conclusions: Participants receiving BUP/NX 3 times weekly were more likely to reduce opioid injection while on active treatment. Both treatment strategies were considered safe and associated with reductions in injection-related risk behavior. These data support the use of thrice-weekly BUP/NX as a way to reduce exposure to HIV risk. Continued access to BUP/NX may be required to sustain reductions in opioid use. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone: HIV Prevention Trials Network 058
Conclusions: Participants receiving BUP/NX 3 times weekly were more likely to reduce opioid injection while on active treatment. Both treatment strategies were considered safe and associated with reductions in injection-related risk behavior. These data support the use of thrice-weekly BUP/NX as a way to reduce exposure to HIV risk. Continued access to BUP/NX may be required to sustain reductions in opioid use. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.